Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RNA NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRNAAvidity Biosciences$49.77-2.0%$45.07$21.51▼$56.00$7.26B0.972.98 million shs2.24 million shsSRPTSarepta Therapeutics$22.11-4.4%$19.11$10.41▼$138.81$2.16B0.516.55 million shs4.51 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRNAAvidity Biosciences-1.97%+5.89%+7.26%+58.25%+8.76%SRPTSarepta Therapeutics-4.41%-2.34%+28.40%+21.68%-81.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRNAAvidity Biosciences$49.77-2.0%$45.07$21.51▼$56.00$7.26B0.972.98 million shs2.24 million shsSRPTSarepta Therapeutics$22.11-4.4%$19.11$10.41▼$138.81$2.16B0.516.55 million shs4.51 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRNAAvidity Biosciences-1.97%+5.89%+7.26%+58.25%+8.76%SRPTSarepta Therapeutics-4.41%-2.34%+28.40%+21.68%-81.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRNAAvidity Biosciences 2.95Moderate Buy$68.3237.26% UpsideSRPTSarepta Therapeutics 2.03Hold$34.4255.66% UpsideCurrent Analyst Ratings BreakdownLatest RNA and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025RNAAvidity BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SRPTSarepta TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$14.00 ➝ $16.009/27/2025RNAAvidity BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SRPTSarepta TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/22/2025RNAAvidity BiosciencesEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$70.00 ➝ $65.009/22/2025SRPTSarepta TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$50.009/17/2025RNAAvidity BiosciencesRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$62.009/15/2025RNAAvidity BiosciencesBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $65.009/15/2025SRPTSarepta TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.009/12/2025RNAAvidity BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$68.00 ➝ $87.009/10/2025RNAAvidity BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $65.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRNAAvidity Biosciences$10.90M666.19N/AN/A$11.94 per share4.17SRPTSarepta Therapeutics$1.90B1.14$2.44 per share9.08$15.99 per share1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRNAAvidity Biosciences-$322.30M-$3.56N/AN/AN/A-4,247.77%-33.45%-30.22%11/6/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A2.02N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)Latest RNA and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025RNAAvidity Biosciences-$1.09N/AN/AN/A$1.80 millionN/A11/5/2025Q3 2025SRPTSarepta Therapeutics$0.02N/AN/AN/A$331.51 millionN/A8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRNAAvidity BiosciencesN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRNAAvidity BiosciencesN/A9.269.26SRPTSarepta Therapeutics0.842.891.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRNAAvidity BiosciencesN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipRNAAvidity Biosciences3.83%SRPTSarepta Therapeutics7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRNAAvidity Biosciences190145.90 million140.32 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableRNA and SRPT HeadlinesRecent News About These CompaniesSarepta Therapeutics: A Discounted Valuation Meets Breakthrough PipelineOctober 10 at 11:50 AM | seekingalpha.comSarepta Therapeutics (SRPT) Receives a Hold from Mizuho SecuritiesOctober 10 at 9:16 AM | theglobeandmail.comSarepta Therapeutics (SRPT) Receives a Buy from JefferiesOctober 10 at 9:16 AM | theglobeandmail.comWhat's Going On Sarepta Stock On Wednesday?October 8 at 11:19 AM | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up After Analyst UpgradeOctober 8 at 10:38 AM | marketbeat.comRoyal Bank Of Canada Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $16.00October 8 at 9:39 AM | marketbeat.comA Look at Sarepta Therapeutics (SRPT) Valuation Following Recent Share Price GainsOctober 6, 2025 | finance.yahoo.com25,360 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by 111 CapitalOctober 6, 2025 | marketbeat.comSarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial ResultsOctober 3, 2025 | insidermonkey.comSarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian PlayOctober 3, 2025 | seekingalpha.comSarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society CongressOctober 3, 2025 | businesswire.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from AnalystsOctober 3, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Trading Up 10.4% - What's Next?October 2, 2025 | marketbeat.comGenerali Investments CEE investicni spolecnost a.s. Grows Position in Sarepta Therapeutics, Inc. $SRPTOctober 1, 2025 | marketbeat.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 30, 2025 | businesswire.comTempus Wealth Planning LLC Has $353,000 Holdings in Sarepta Therapeutics, Inc. $SRPTSeptember 29, 2025 | marketbeat.comCantor Fitzgerald Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)September 25, 2025 | theglobeandmail.comSarepta Therapeutics (SRPT) Receives a Hold from Evercore ISISeptember 25, 2025 | theglobeandmail.comKuehn Law Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law FirmSeptember 24, 2025 | prnewswire.comAssenagon Asset Management S.A. Purchases 155,358 Shares of Sarepta Therapeutics, Inc. $SRPTSeptember 23, 2025 | marketbeat.comBMO upgrades Sarepta on Elevidys uptake, pipeline prospectsSeptember 22, 2025 | au.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNA and SRPT Company DescriptionsAvidity Biosciences NASDAQ:RNA$49.77 -1.00 (-1.97%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$49.00 -0.78 (-1.56%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Sarepta Therapeutics NASDAQ:SRPT$22.11 -1.02 (-4.41%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$21.58 -0.53 (-2.40%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
